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Abstract
Introduction: Transsphenoidal surgery (TSS) is the treatment of choice for Cushing`s disease (CD). A proper assessment of the efficacy of 
surgical treatment is crucial in terms of patient prognosis. The aim of this study was to evaluate the usefulness of serum cortisol measure-
ments performed on the first post-operative day as a predictor of TSS outcome. 
Material and methods: This prospective study involved 36 patients with CD who were operated on using the same surgical protocol and 
followed up for at least 18 months (median: 30 months). We investigated the relationship between serum cortisol measurements performed 
on the first post-operative day and the hormonal assessment of the pituitary-adrenal axis performed after 18 months of follow-up. The 
adopted criteria for remission were: serum cortisol within the referral range, normal circadian rhythm, and the ability of serum cortisol to 
suppress to values ≤ 1.8 μg/dL after 1 mg of dexamethasone.
Results: The median serum cortisol on the first post-operative day was 1.98 μg/dL. 23 patients (63.9%) were regarded as cured. In all these 
cured cases, the post-op cortisol was ≤ 2.5. On the other hand, in the cases of the 13 patients (36.1%) for whom the remission of CD was 
not confirmed, the post-op cortisol was ≥ 2.5.
Conclusion: Our prospective study demonstrated that early post-operative serum cortisol measurements can serve as a simple and use-
ful test that predicts the remission of CD. Furthermore, a post-operative cortisol ≤ 2.5 can be considered as a forecast of CD remission. 
(Endokrynol Pol 2013; 64 (1): 30–39)
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Streszczenie
Wstęp: Leczeniem z wyboru w chorobie Cushinga jest selektywna przezklinowa adenomectomia. Ocena skuteczności operacji ma 
kluczowe znaczenie z punktu widzenia rokowania chorych. Celem pracy była prospektywna ocena przydatności oznaczeń kortyzolu 
w surowicy wykonanych w 1 dobie po operacji przezklinowej gruczolaka kortykotropowego dla oceny skuteczności leczenia operacyjnego.
Materiał i metody: Badanie prospektywne obejmujące 36 pacjentów z chorobą Cushinga operowanych według identycznego protokołu 
operacyjnego i obserwowanych przez co najmniej 18 miesięcy (mediana: 30 mies.). Oceniano związek pomiędzy stężeniem kortyzo-
lu w surowicy o godzinie 6.00 w 1 dobie po operacji przezklinowej a oceną hormonalną osi przysadkowo-nadnerczowej wykonaną 
w 18 miesiącu obserwacji pooperacyjnej. Jako kryteria remisji przyjęto: normalizację stężenia kortyzolu w surowicy, prawidłowy rytm 
dobowy oraz obniżenie stężenia kortyzolu do wartości poniżej 1,8 μg/dl w teście z 1 mg deksametazonu.
Wyniki: Mediana stężenia kortyzolu w 1 dobie po operacji przysadki wyniosła 1,98 μg/dl. 23 pacjentów (63,9%) zostało uznanych za 
wyleczonych z choroby Cushinga. We wszystkich tych przypadkach stężenie kortyzolu w surowicy w 1 dobie po operacji było mniejsze 
lub równe 2,5 μg/dl. Jednocześnie u żadnego z 13 pacjentów (36,1%) ze stężeniem kortyzolu w 1 dobie po operacji powyżej 2,5 μg/dl nie 
potwierdzono remisji choroby Cushinga. 
Wnioski: W badaniu prospektywnym wykazano, iż wczesne, pooperacyjne oznaczanie stężenia kortyzolu w surowicy jest prostym 
i użytecznym badaniem zapowiadającym remisję choroby Cushinga. Wykazanie stężenia kortyzolu w surowicy mniejszego 
lub równego 2,5 μg/dL w 1 dobie po operacji przezklinowej może być traktowane jako czynnik prognozujący remisję choroby. 
(Endokrynol Pol 2013; 64 (1): 30–39)
Słowa kluczowe: choroba Cushinga, gruczolak przysadki, kortyzol, operacja przezklinowa, guz kortykotropowy
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Introduction
Cushing’s disease (CD) is one of the biggest challenges in 
contemporary endocrinology. It is caused by a pituitary, 
corticotroph adenoma producing adrenocorticotropic 
hormone (ACTH). Increasing corticotrophin secretion 
leads to cortisol excess and typical clinical symptoms 
[1–5]. Gradually, organ complications develop, such as 
arterial hypertension, impaired glucose tolerance and 
diabetes, decreased bone mineral density and increased 
risk of infections. They result in impaired quality of life 
and reduced life expectancy [3, 6–10]. Currently, TSS is 
the treatment of choice [3, 11–13]. The effectiveness of 
the surgical procedure in reference centres is excellent, 
with a success rate reaching as high as 90%. The suc-
cess rate of TSS depends on several factors including 
the precise, pre-operative localisation of the pituitary 
tumour in magnetic resonance imaging (MRI) [11, 
14–16], the immunohistochemical confirmation of the 
presence of a corticotroph tumour [15, 18, 19], the post-
operative decrease in serum cortisol level [10, 20–23], 
and the experience of the neurosurgeon. Following TSS, 
patients are referred to endocrinological units to assess 
the efficacy of the surgical treatment and to monitor the 
post-operative function of the pituitary-adrenal axis. 
However, the laboratory procedures are not uniform 
and adopt different follow-up schedules depending on 
the site. In the literature there is still a lack of prospective 
studies on this important issue. 
Therefore, the aim of this study was to prospectively 
evaluate the utility of early post-operative serum cortisol 
measurements performed on the first post-operative 
day for the remission of CD and to determine the cut-off 
point of the serum cortisol level that enables a predic-
tion of remission. 
Material and methods
Patient population
The study population consisted of 36 patients with CD 
(30 women and six men; F:M ratio: 5:1) hospitalised in 
the Department of Endocrinology, the Medical Centre 
of Postgraduate Education between 2005 and 2009. The 
mean age was 36.3 ± 12.9 years (range 16.8 to 57.6 years). 
After a confirmed diagnosis of CD, the patients were 
referred to the Department of Neurosurgery, Military 
Institute of Medicine in Warsaw. They were all oper-
ated on by the same neurosurgeon using an identical 
surgical protocol.
All patients were informed about the aims and 
methods of the study and they signed the informed 
consent. The study protocol was approved by the Bio-
ethics Committee at CMKP.
Clinical course of CD and pre-operative  
endocrine evaluation
The diagnosis of ACTH-dependent Cushing’s syndrome 
(CS) was made based on the clinical signs and standard 
hormonal criteria: increased urinary excretion of UFC 
(urinary free cortisol) or 17-OHCS (17-hydroxysteroids), 
increased serum cortisol level at 8.00am, the loss of 
cortisol circadian rhythm (a serum cortisol level above 
7.5 μg/dL in the late night hours, increased or detectable 
plasma ACTH at 8.00am and the failure of serum cortisol 
to suppress to a level ≤ 1.8 during a low dose dexametha-
sone suppression test (LDDST; 0.5mg q.i.d. for 48 hours). 
The pituitary aetiology of CS was confirmed based on 
a serum cortisol and UFC or 17-OHCS suppression 
greater than 50% on a high dose dexamethasone sup-
pression test (HDDST; 2mg q.i.d. for 48h) and positive 
MRI. In the case of equivocal results of the hormonal 
assessment and pituitary imaging, the diagnosis of CD 
was confirmed by a positive result in a stimulation test 
with an intravenous CRH injection (100 μg). 
Pre-operative MR imaging
Prior to TSS, all patients underwent high resolution MRI of 
the pituitary-hypothalamic region (SIEMENS Symphony 
2004; 1.5 Tesla). The MRI scans were performed before and 
after an intravenous injection of gadolinium (Gd-DTPA). 
It was determined that the presence of a hypodense 
lesion after contrast indicated a pituitary adenoma. 
A microadenoma was defined as a pituitary tumour with 
a diameter of less than 1 cm in any dimension, whereas 
a macroadenoma was defined by the presence of a tumour 
with at least one diameter of more than 1 cm. The MRI 
was qualified as equivocal if the pituitary tumour was not 
precisely visualised or if only indirect traits of the tumour 
were present, such as the deviation of the pituitary stalk 
or a convex upper surface of the pituitary gland.
Surgical procedure
In all cases, a microsurgical transseptal transsphenoi-
dal approach was used for the resection of an ACTH-
secreting pituitary adenoma. The sella was exposed 
and the H-shaped incision of the dura was made. 
The dura mater was opened and separated from the 
pituitary capsule to expose the entire anterior surface 
of the pituitary gland. Then the pituitary gland was 
carefully explored, regardless of MRI findings. Selective 
adenomectomy was performed in all cases of visualised 
pituitary adenoma on MR imaging. When the MR was 
equivocal, or no tumour was evident, a series of verti-
cal and horizontal incisions of the pituitary gland was 
carried out and all tissue deemed to be abnormal was 
removed and submitted for pathological examination. 
In patients where no abnormal tissue could be identified 
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intra-operatively, hemihypophysectomy, subtotal hypo-
physectomy, or total hypophysectomy was performed. 
Histopathological and immunohistochemical 
assessment
The surgical specimen was collected for histopathologi-
cal analysis (standard haematoxylin and eosin staining) 
and immunohistochemical staining for pituitary hor-
mones. The result was considered positive if the pres-
ence of ACTH-staining in the immunohistochemical 
examination was confirmed. The result was treated as 
negative if there was no evidence of the corticotroph 
adenoma and ACTH-staining was negative.
Post-operative hormonal evaluation  
and criteria of a cure
Blood samples for serum cortisol measurements were 
collected from all patients at 6.00am on the first post-
operative day. Glucocorticoids were not administered in 
the perioperative nor in the early post-operative period. 
Hydrocortisone replacement therapy was started after 
biochemical confirmation of hypocortisolaemia or the 
development of clinical symptoms of adrenal insuf-
ficiency. In such cases, the hydrocortisone was given 
intravenously in a daily dose 50 mg t.i.d. during the 
first two post-operative days. Afterwards the standard 
dose of hydrocortisone (20 mg in the morning and 10 
mg at 3.00 pm) was started and continued until the next 
hormonal evaluation. 
Following the surgical procedure, all patients were 
subjected to further evaluation lasting at least 18 months 
(median 30 months; range 18–36 months). The first 
biochemical evaluation of corticotroph function was 
performed within seven days from TSS. Subsequent 
reassessments were performed at six weeks and 3, 6, 12, 
18, 24 and 36 months after surgery. Patients on hydrocor-
tisone replacement therapy had their cortisol measure-
ments taken 48 hours after the last administered dose. 
The patients were regarded as cured if they fulfilled 
the following criteria for remission: clinical and bio-
chemical evidence of eucortisolaemia: morning serum 
cortisol within referral range, the correct circadian 
rhythm (the late night serum cortisol level ≤ 7.5 μg/ 
/dL), and the ability of serum cortisol to suppress to less 
than or equal to 1.8 μg/dL following the overnight 1 mg 
dexamethasone suppression test (ODST).
Hormone assay
Chemiluminescent immunometric assays (IMMULITE 
2000, Siemens, Great Britain) were used to measure 
serum cortisol. The method sensitivity was 0.2 μg/dL 
(5.5 nmol/L). The normal range for cortisol was 5–25 μg/dL 
(138–690 nmol/L). The lowest limit of quantification for 
cortisol, using the IMMULITE 2000 analyser, was the 
measured value of 1.0 μg/dL. For the purpose of further 
calculations it was assumed that in these cases the post-
op cortisol was 1.0. Plasma ACTH was measured using 
a two-step radioimmunometric assay (IRMA; coated 
tube technique, Brahms, Germany). Method sensitivity 
was 1.2 pg/mL and the referral range was 10 to 60 pg/mL. 
Statistical analysis
Methods of descriptive statistics (mean, median, 
standard deviations, proportion) were employed 
in the statistical analysis. Verification of hypotheses 
concerning the relationship between two categori-
cal variables were expressed as frequencies and 
compared using the exact chi-square test (Fisher ’s 
exact test). The significance of differences between 
average values of continuous variable in two groups 
was analysed by means of the Student`s t-test for 
a normal distribution and the Mann-Whitney test for 
small samples when its distribution was not normal. 
Verification of hypotheses concerning comparisons 
of the analysed parameters in two time points was 
conducted using the Wilcoxon test for small samples 
(for non-normal distributions). 
The dynamics of analysed tests results was con-
ducted by calculating areas under the curve (AUC) 
using a trapezoid method. The significance of dif-
ferences between these areas was checked using the 
Mann-Whitney test. In order to present values of aver-
age areas under the curve, the individual values were 
logarithmically transformed and the standard errors for 
logarithm values were calculated. 
The level of significance was set at p < 0.05. The cal-
culations were made using the commercially available 
statistical software package SPSS v. 18.0.
Results
Results of clinical and epidemiological  
assessment
The clinical characteristics covering demographic data, 
complications of CD, number of operations, results of 
the pre-operative MRI and histopathological examina-
tion are presented in Table I.
Results of early post-operative  
hormone evaluation
The mean first day post-operative serum cortisol was 6.0 
± 9.02 μg/dL (median: 1.975; range: 1.0 to 37.0) v. 25.9 
± 7.35 μg/dL (median: 26.05; range:14.4 to 41.3) prior 
to surgical treatment (p < 0.001).
Detailed results of first day post-operative cortisol 
after TSS for CD are presented in Table II. Patients were 
ranked in ascending order based on the results of their 
first day post-op cortisol. 
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The 36 patients were then divided into three sub-
groups, depending on their first day post-operative 
cortisol levels. Subgroup 1 consisted of 19 subjects with 
very low cortisol concentrations, i.e. with post-op cor-
tisol levels ≤ 2.0. The cut-off of 2.0 μg/dL was selected 
based on the median value of 1.975. Subgroup 2 con-
sisted of five patients whose serum cortisol was higher 
and judged to be detectable (above median value) but 
still below the lower limit 5.0 μg/dL of the referral range, 
i.e. with cortisol levels between 2.0 and 5.0. Subgroup 
3 consisted of 12 patients (33.3%) with cortisol concen-
trations within or above the laboratory range, i.e. with 
serum cortisol above 5.0 μg/dL. 
Results of further post-operative  
hormone evaluation
The serum cortisol measurements during the follow-up 
period were conducted at 6.00am on the seventh post-
operative day, and 1.5, 3, 6, 12, 18, 24 and 36 months 
after surgery. The detailed results presented as mean 
± SD, median values and ranges are set out in Table III.
Based on a hormonal evaluation performed 
18 months after surgery, the efficacy of the TSS was as-
sessed for all 36 patients. The patients were regarded 
as surgically cured from CD if they fulfilled all of 
the following criteria of remission: morning serum 
cortisol level within the referral range (or persistent 
adrenal insufficiency), normal circadian rhythm of 
serum cortisol and serum cortisol level below 1.8 μg/
dL following a 1 mg dexamethasone suppression test. 
It was established that the above criteria for a cure 
from CD were met by 23 patients (63.9%). Thirteen 
patients (36.1%) who failed to meet the criteria of 
remission were regarded as non-cured subjects. De-
tailed results of the final hormonal assessment are 
presented in Table II.
A significant difference was confirmed between 
cured and non-cured subjects in terms of morning 
serum cortisol concentrations (p < 0.001) and serum 
cortisol levels following ODST (p < 0.001). The detailed 
results are presented in Table IV. 
At the next stage of the study, on the basis of the 
hormone evaluation conducted in the course of the 
follow-up, the initial division of the studied group into 
three subgroups was carefully re-assessed. The initial 
allocation (which was based on the results of first day 
serum cortisol) was analysed from the perspective of 
further serum cortisol dynamics, as well as clinical and 
biochemical assessments performed at the end of the 
18-month follow-up. 
Due to the fact that the distribution of poc was not 
normal, the upper cut-off point for Subgroup 1 was ini-
tially assumed as the median value (1.975, rounded up 
to 2.0 μg/dL). It appears that this group of subjects may 
be regarded as cured. This is confirmed by low serum 
cortisol levels achieved in the course of the 18-month 
Table I. Demographic data and pre-operative clinical characteristics of the study group of 36 patients with CD
Tabela I. Dane demograficzne oraz przedoperacyjna charakterystyka kliniczna badanej grupy 36 pacjentów z chorobą Cushinga
Number of patients 36
Age (years) mean ± SD 
(range)
36.3 ± 12.9 
(16.8–57.6)
Sex Females n (%) 30 (83.3%)
Males n (%) 6 (16.7%)
Complications of CD Hypertension n (%) 28 (77.8%)
Diabetes n (%) 6 (16.7%)
Pre-diabetes n (%) 12 (33.3%)
Ø BMD (osteopenia or 
osteoporosis)
n (%) 26 (72.2%)
Obesity (BMI ≥ 30) n (%) 13 (36.1%)
Surgical treatment First n (%) 28 (77.8%)
Subsequent operation n (%) 8  (22.2%)
The follow-up period (months) mean ± SD 
(range)
28.5 ± 7.9 
(18–36)
MRI results Microadenoma 22 (61.1%)
Macroadenoma 6 (16.7%)
Equivocal MRI 8 (22.2%)
Histopathology  
(light microscopy)
Positive n (%) 27 (75%)
Negative n (%) 9 (25%)
34
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
Transsphenoidal surgery for Cushing’s disease  Przemysław Witek et al.
Table II. Detailed results of serum cortisol measurements on the first day, at six and 12 months after TSS, along with hormonal 
evaluation of the pituitary-adrenal axis conducted at the end of the follow-up period 
Tabela II. Szczegółowe wyniki oznaczeń kortyzolu w 1. dobie oraz 6 i 12 miesięcy po operacji wraz z podsumowaniem funkcji 
osi przysadkowo-nadnerczowej na zakończenie 18-miesięcznej obserwacji
Demografic data Serum 
cortisol 1st 
day after 
TSS [µg/dL] 
Serum 
cortisol 6 
month after 
TSS [µg/dL]
Serum 
cortisol 12 
month after 
TSS [µg/dL]
Final hormonal assessment at the end of follow-up 
(18 month)
No. Sex Age 
(years)
Cortisol  
8.00
Circadian 
rhytm
ODST Remission
1 F 52.6 < 1.0 < 1.0 13.8 10.36 N < 1.0 Yes
2 F 24.8 < 1.0 14 17.7 10.5 N < 1.0 Yes
3 F 26.3 < 1.0 < 1.0 < 1.0 1.81 * ** Yes
4 M 19.9 < 1.0 < 1.0 4.2 16.4 N < 1.0 Yes
5 F 52.4 < 1.0 5.46 6.55 4.57 N < 1.0 Yes
6 F 26.2 < 1.0 < 1.0 3.48 10.9 N < 1.0 Yes
7 F 57.2 < 1.0 7.06 5.25 10.2 N 1.38 Yes
8 F 43.7 1.08 < 1.0 4.5 5.29 N 1.6 Yes
9 F 28.0 1.14 2.02 2.19 < 1.0 * ** Yes
10 F 29.9 1.2 < 1.0 12.6 10.9 N < 1.0 Yes
11 F 34.4 1.2 1.81 2.92 9.04 N < 1.0 Yes
12 F 51.0 1.6 2.97 2.13 2.84 N 1.54 Yes
13 F 41.0 1.4 13.9 7.51 11.9 N < 1.0 Yes
14 F 29.1 1.6 3.87 8.0 9.7 N < 1.0 Yes
15 F 29.7 1.6 3.25 6.0 14.1 N 1.1 Yes
16 M 20.9 1.69 < 1.0 12.7 14.3 N < 1.0 Yes
17 F 18.4 1.79 6.72 10.4 8.65 N < 1.0 Yes
18 F 40.8 1.95 8.85 8.62 6.98 N 1.37 Yes
19 F 24.3 2.0 14.2 12.3 13.9 N < 1.0 Yes
20 F 26.3 2.04 9.03 18.6 10.2 N 1.13 Yes
21 F 25.1 2.05 < 1.0 1.28 6.49 N 1.23 Yes
22 F 56.3 2.17 4.41 3.92 13.6 N < 1.0 Yes
23 F 52.1 2.5 2,4 3.15 8.36 N 1.71 Yes
24 F 57.6 4.08 12.7 19.2 15.5 A 3.69 No
25 F 34.1 5.3 19.8 17.6 16.8 A 9.04 No
26 F 28.4 5.5 9.74 8.1 14.6 A 3.45 No
27 F 34.8 6.5 10.1 17.7 13.5 N 3.67 No
28 M 49.3 6,7 15.5 12.6 23.7 A 4.3 No
29 F 55.8 6.6 9.4 11.4 11.6 N 3.2 No
30 M 16.8 8.7 14.2 16.3 14.8 A 8.79 No
31 F 32.1 9.2 7.4 9.7 14.4 A 8.47 No
32 F 32.4 17.5 22.6 29.7 32.4 A 17.8 No
33 M 39.8 19.7 11.7 11.0 33.1 A 7.72 No
34 M 18.8 20.1 9.61 31.6 28.5 A 6.38 No
35 F 53.8 35.5 16.3 23.1 18.3 A 11.7 No
36 F 42.5 37.0 14.0 8.97 27.3 A 8.7 No
Abbreviations: ODST — overnight (1 mg) dexamethasone suppression test;  N — normal;  A — abnormal;   
*due to subnormal serum cortisol concentrations the assessment  of circadian rhythm was not possible  (secondary adrenal insufficiency) 
**due to undetectable cortisol levels, ODST was not performed 
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follow-up, remission of clinical symptoms of hypercor-
tisolaemia, and restoration of normal circadian cortisol 
rhythm, as well as further results of ODST. 
Further analysis of the serum cortisol dynamics in 
the post-operative period, abnormal circadian rhythm, 
the results of ODST as well as somatic features of per-
sistent CD did not allow a diagnosis of remission in 
Subgroup 3 (serum cortisol > 5.0 μg/dL). Thus, every 
studied subject with serum cortisol concentration within 
or above the limits of laboratory range may be regarded 
as a patient with persistent CD or at higher risk of hy-
percortisolaemia recurrence. 
For the patients in Subgroup 2, a detailed assessment 
of cortisol dynamics was conducted in the 18 month 
period after surgery, separately for each subject studied 
(Table V). This was followed by a comparison of the 
serum cortisol levels of all three subgroups on the first 
day after surgical treatment and at three consecutive 
time points (seventh day, sixth week and third month 
after TSS). 
Table III. Detailed results of serum cortisol concentration conducted before TSS, on the first day after surgical treatment, and 
at consecutive time points of the 18-month follow-up period, presented as mean ± SD, median and ranges. The available data 
for the 24th and 36th months of follow up was added
Tabela III. Wyniki oznaczeń kortyzolu w surowicy przed operacją przezklinową, w 1. dobie po leczeniu operacyjnym oraz w 
kolejnych punktach czasowych 18-miesięcznej obserwacji, przedstawione w postaci wartości średnich ± SD, median i zakresu 
danych (min.–max.). Przedstawiono również dostępne dane dla 24. i 36. miesiąca po leczeniu operacyjnym 
Cortisol [µg/dL]
before TSS
Postoperative serum cortisol concentration in consecutive time points [µg/dL]
1st day 7th days 6 weeks 3 months 6 months 12 months 18 months 24 months 36 months
N 36 36 36 36 36 36 36 36 27 18
Mean 25.91 6 6.49 6.48 6.57 7.81 10.72 12.99 15.54 14.99
Median1 26.05 1.975 1.27 2.15 4.43 7.23 9.34 11.75 13.4 15.3
SD 7.35 9.02 9.36 8.08 5.88 6.08 7.59 7.54 9.38 6.69
Minimum 14.40 1.0 1.0 1.0 1.0 1.0 1.0 1.0 3.9 6.64
Maximum 41.30 37 40.9 31.3 23.8 22.6 31.6 33.1 50.0 32.1
1Due to non-normal serum cortisol distribution the median values were marked out
Table IV. Serum cortisol level under basic conditions and following 1 mg dexamethasone suppression test in the cured and 
non-cured groups
Tabela IV. Porównanie stężenia kortyzolu w warunkach podstawowych i w teście hamowania 1 mg deksametazonu w grupie 
wyleczonej i niewyleczonej
All operated subjects Cured subjects Non-cured subjects p
Serum cortisol 8.00
(18  months)
N 36 23 13
< 0.001
Mean 12.99 9.2 19.65
SD 7.54 4.12 7.7
Median 11.75 10.2 15.5
Minimum 1.0 1.0 11.6
Maximum 33.1 16.4 33.1
Serum cortisol 8.00
 (after 1 mg of 
dexamethazon)
N 36 21* 13
< 0.001
Mean 3.56 1.14 7.46
SD 3.99 0.24 4.14
Median 1.375 1 7.72
Minimum 1 1 3.2
Maximum 17.8 1.71 17.8
*ODST was not performed in two cured subjects due to persistent adrenal insufficiency
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As a result of the analysis conducted, it was estab-
lished that four patients (patients no. 20–23) with serum 
cortisol lower than or equal to 2.5 μg/dL did not differ 
(in terms of cortisol concentrations during follow-up) 
from subjects in the group regarded as cured (Table V). 
This was proven by very low (subnormal) serum cortisol 
levels on the seventh day, sixth week and third month 
after surgery for corticotroph adenoma. Furthermore, 
in these four patients, there were also identified clinical 
features of remission, the serum cortisol measured at the 
end of the follow-up was normal, the circadian rhythm 
was preserved, and the ability of serum cortisol to sup-
press to less than 1.8 μg/dL following LDDST was main-
tained. However, one studied subject with cortisol 4.08 
μg/dL (patient no. 24) did not differ significantly from 
the subjects regarded as non-cured. This was proven by 
a rapid increase in cortisol concentration after surgery, 
abnormal circadian cortisol rhythm and an inability of 
serum cortisol to suppress to a value below 1.8 μg/dL. 
The above analysis shows that a threshold value of 2.5 
μg/dL for first day post-operative serum cortisol could be 
regarded as being predictive of remission in CD. 
To summarise the results of our work, we observe 
that all 23 patients who met the criteria of remission of 
CD had serum cortisol concentration on the first day 
after TSS lower than or equal to 2.5 μg/dL, whereas 
remission of CD was not confirmed in any of the 13 
patients with a post-operative cortisol concentration 
higher than 2.5 μg/dL. 
Discussion
The aim of the neurosurgical treatment of CD is to 
completely remove pituitary corticotroph adenoma. 
Currently, the treatment of choice is transsphenoidal 
selective adenomectomy. The most desirable result of 
the procedure is selective removal of pituitary tumour 
in such a manner as to maintain normal thyreo- and 
gonadotrophic function of the anterior pituitary and 
to leave the posterior lobe undamaged. The high se-
lectivity of TSS allows the gradual recovery of normal 
corticotroph pituitary function, which was crushed by 
the long-term sustained overproduction of ACTH and 
cortisol. Obviously, such high selectivity of surgery is 
not always possible. In the case of repeat TSS, or in the 
presence of invasive macroadenomas, the scope of per-
formed surgery is often wider — hemihypophysectomy 
or (in severe, selected cases) total hypophysectomy is 
performed [11–13,24]. 
Irrespective of the scope of the TSS, complete re-
moval of autonomous neoplastic tissue results in cortisol 
deficiency and sequential symptoms of secondary adre-
nal insufficiency, because normal pituitary corticotroph 
function was suppressed by high ACTH and cortisol 
Table V. Serum cortisol concentrations on the first day after TSS and in consecutive time points of 18 months follow-up. A 
detailed analysis of five patients with serum cortisol on first day within the range of 2-5 μg/dL compared to median cortisol 
concentration levels in groups regarded as cured (cortisol level ≤ 2.0 μg/dL) and non-cured (cortisol level ≥ 5μg/dL)
Tabela V. Stężenia kortyzolu w 1. dobie po operacji oraz w kolejnych punktach czasowych 18-miesięcznej obserwacji. Szczegółowa 
analiza 5 przypadków ze stężeniami kortyzolu w 1. dobie po operacji w przedziale od 2 μg/dl do 5 μg/dl zestawiona z medianą 
stężenia kortyzolu dla grupy uznanej za wyleczoną (≤ 2.0 μg/dl) i niewyleczoną (≥ 5μg/dl)
1st day serum 
cortisol [µg/dL]
Postoperative serum cortisol concentration (µg/dL) 
1st day 7th days 6 weeks 3 months 6 months 12 months 18 months
≤ 2.0
 
N 19 19 19 19 19 19 19
Mean 1.32 1.23 1.66 3.33 4.8 7.47 9.12
SD 0.35 0.46 0.99 2.7 4.75 4.68 4.38
Median 1.2 < 1.0 < 1.0 3.04 2.97 6.55 10.2
2.01–4.99
Pt No. 20 2.04 < 1.0 < 1.0 2.85 9.03 18.6 10.2
Pt No. 21 2.05 < 1.0 < 1.0 < 1.0 < 1.0 1.28 6.49
Pt No. 22 2.17 < 1.0 < 1.0 1.5 4.41 3.92 13.60
Pt No.23 2.5 3.96 3.61 3.17 2.4 3.15 8.36
Pt No. 24 4.08 5.12 10.3 10.7 12.7 19.2 15.5
≥ 5.0
N 12 12 12 12 12 12 12
Mean 14.86 16.51 15.39 12.82 13.36 16.45 20
SD 11.39 10.6 8.32 5.32 4.6 7.87 7.93
Median 8.95 14.4 14.75 11.7 12.85 14.45 15.2
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excess. Due to the relatively short half-life of serum cor-
tisol (about 60 minutes) the post-operative decrease in 
serum cortisol is rapid. Therefore, after about four hours 
following TSS, serum cortisol concentration should be 
lowered by about 90%, and after seven hours it should 
be less than 1% of its initial value. 
One of the relatively few prospective works that 
discuss this issue is the study by Rollin et al. on the dy-
namics of cortisol concentration at six, 12 and 24 hours 
after surgery, conducted on 26 patients with Cushing’s 
disease [22]. Twelve hours after TSS, these authors 
found a significant difference in cortisol concentrations 
between the cured and the non-cured group. Twenty 
four hours after surgery, the mean cortisol concentra-
tion in the cured group was 4.72 ± 6.72 μg/dL. This was 
higher than the concentration observed in our group 
(mean 1.5 ± 0.47 μg/dL; median: 1.36 μg/dL). It is worth 
noting that the criteria for a cure adopted in the present 
study are more stringent. The criteria for a cure adopted 
by Rollin were that the serum cortisol concentration 
following 1 mg dexamethasone suppression test should 
be ≤ 3 μg/dL, clinical improvement, and the need for 
hydrocortisone replacement therapy. 
In our study, it was assumed that following a 1 mg 
dexamethasone suppression test an effectively cured 
patient should behave like a healthy individual, and 
that therefore the measured serum cortisol concentra-
tion should not exceed 1.8 μg/dL as recommended by 
the current consensus [25]. Clinical improvement and 
the necessity of hydrocortisone replacement may also 
be misleading. They may result from a merely partial 
lesion removal and sequential ischaemia occurring in 
the course of intraoperative manipulation and they do 
not constitute evidence, in the strict sense, of disease 
cure. Thus, in the group regarded as ‘cured’ by Rollin, 
there might have been patients with persistent, so-called 
‘smouldering’ Cushing’s disease. 
The cut-off point of cortisol concentration on the 
first day after TSS of ≤ 2.5 μg/dL achieved in our study 
is lower than the threshold reported in the retrospective 
study of Esposito et al. on the material of 40 patients 
with CD from two American centres. Initially, the cut-off 
value assumed in this study was 8 μg/dL. However, this 
was lowered due to the fact that none of the studied 
patients demonstrated a post-operative serum cortisol 
concentration within the range of 5–8 μg/dL [20]. In our 
study, the female patient (patient no. 24) with cortisol 
= 4.08 μg/dL demonstrated features of recurrence of 
hypercortisolaemia, which was later confirmed by the 
results of hormone dynamic testing [26]. 
It should be emphasised here that to obtain credible 
results of early cortisol measurements it is necessary to 
refrain from administering hydrocortisone replacement 
in the post-operative period until serum cortisol meas-
urements are performed at 6.00am on the following day, 
or until the symptoms of adrenal insufficiency occur. 
Contrary to previous concerns and suggestions, which 
required routine administration of hydrocortisone [12, 
27,28], such a procedure appears to be safe [20, 22]. This 
is probably associated with the cellular mechanism of 
cortisol action towards cytoplasmic and nuclear recep-
tors and transcription processes, which are significantly 
increased with cortisol excess. Therefore, a several-hour 
delay in initiation of hydrocortisone replacement does 
not lead to the development of adrenal crisis as early 
as on the first post-operative day. The possible risk of 
developing adrenal crisis is also mitigated by the renin-
angiotensin-aldosterone system, which is responsible 
for maintaining an appropriate volume of body fluids. 
Its function in secondary adrenal insufficiency is not 
impaired. Some significance should also be attributed 
to the fact that TSS is a relatively safe and minimally 
invasive surgical procedure [13, 29, 30]. 
In the 2008 consensus statement on the treatment 
of CD, great importance was attached to post-operative 
serum cortisol concentration and urinary free cortisol. 
There are, however, no indications as to the specific 
point in time at which the measurements should be per-
formed. The consensus statement also recommended 
considering patients with a serum cortisol concentra-
tion of less than or equal to 5 μg/dL to be surgically 
cured [11]. Fomekong et al. performed post-operative 
cortisol concentration measurements on the second and 
fifth days after TSS, and they initiated hydrocortisone 
substitution when the serum cortisol concentration was 
lower than 10 μg/dL. The substitution was continued 
until it was confirmed that the morning serum cortisol 
concentration did not exceed 10 μg/dL [31]. Chen et al. 
showed that demonstrating a serum cortisol concentra-
tion lower than or equal to 3 μg/dL following a 1 mg 
dexamethasone suppression test on the third day after 
TSS is of prognostic value with reference to a cure for 
Cushing’s disease [21]. However, in our study, the 1 mg 
dexamethasone suppression test was performed later, 
at the end of the 18-month follow-up period. We found 
it interesting that in every uncured patient it was then 
demonstrated, similarly as in the study by Chen et al., 
that the cortisol concentration after the administration 
of 1 mg dexamethasone exceeded 3 μg/dL.
In the present study, setting the cut-off point at 
the level of 2.5 μg/dL allowed us to identify a group 
of patients, who, after 18 months of follow-up and on 
the basis of the strict criteria we have adopted, could 
be regarded as being cured from CD. The proposed 
early cortisol assessment also meets the basic criterion 
of clinical usefulness, such as ease and availability of 
serum cortisol determination in basic conditions. At 
the same time, adoption of this threshold value does 
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not exclude possible remission of CD in patients with 
slightly higher cortisol values, although such patients 
were not present in the studied material. 
The principle which must be observed at every stage 
of diagnostics and treatment of Cushing’s disease is to 
avoid drawing conclusions based on single hormone 
determinations or tests, because none of them is consid-
ered to be a gold standard [3, 32–35]. Therefore, in the 
present study, post-operative follow-up was continued 
and cortisol measurements were made particularly 
often during the first year after TSS. The advisability 
of this procedure is confirmed in an interesting retro-
spective study by Valassi et al., which is based on the 
experience of American and Italian centres. The authors 
demonstrated that early post-operative assessment 
(based in the mentioned study on UFC results) may be 
misleading, because in 5.6% of patients with normal or 
even elevated UFC immediately after surgery a signifi-
cant decrease in cortisol concentration was observed 
within the period of 5–8 weeks and remission of CD 
[18]. Similar observations have also been made by other 
authors [36, 37].
In the present study, no cases of delayed remission 
of CD were observed, yet the adopted schedule of cor-
tisol assessment at seven days, six weeks, three months 
and later guarantees detection of possible cases of such 
delayed remission. 
In our opinion, delayed decrease of cortisol concen-
tration may be associated with autonomous cortisol se-
cretion by the adrenals, possibly in connection with the 
sometimes observed nodular hyperplasia of the adrenal 
cortex induced by long-term ACTH stimulation. We 
cannot exclude the influence of degenerative changes 
in the very corticotroph pituitary adenoma, developing 
with delay under the influence of ischaemia induced by 
possible damage during surgical procedures [18, 36, 37]. 
The cases of delayed remission of hypercortisolae-
mia described in the study by Valassi et al. cast doubt 
on the performance of so-called ‘early repeat surgery’ 
in the course of persistent CD, which has been postu-
lated by other authors [38,39]. Qualification for such 
an early repeat TSS was to be conducted on the basis 
of early post-operative hormone assessment. The un-
questionable advantage of this procedure is an attempt 
to perform a second treatment during the same hospital 
stay and by the same operating team. Furthermore, lack 
of cicatrices and adhesions within the surgical access 
is of significant importance and facilitates treatment. 
The optimal time for performance of consecutive TSS 
is debatable; however, it is agreed that it should be 
performed within two weeks of the first procedure [20, 
38, 39]. Observations made by Valassi et al. indicate that 
earlier surgical intervention may unnecessarily expose 
patients to the risk of perioperative complications. 
However, it seems that the 5% probability of delayed 
remission is low, and the procedure of TSS is relatively 
safe [13]. Thus, the surgical team should make the final 
decision, taking into account the specifics of each treated 
patient, including the results of preoperative imaging 
studies and the results of the histopathological examina-
tion from the first surgery. 
In summary, it should be stated that early post-
operative assessment of serum cortisol concentration 
on the first day after TSS for CD is a useful and easy 
diagnostic tool which allows us to make an early dis-
tinction between patients cured from CD, and those 
patients with persistent disease or at increased risk of 
recurrence. The latter group will require particularly 
careful post-operative follow-up and, if necessary, addi-
tional pharmacological treatment, consecutive surgery, 
or radiotherapy [11–13, 40]. 
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